Mir-6880-5p as target for diagnosis and treatment of prostate cancer
The use of miR-6880-5p in exosomes as a biomarker addresses the limitations of existing prostate cancer diagnostics by offering a non-invasive, accurate method for diagnosis and treatment prediction, effectively inhibiting cancer progression and metastasis through targeted interventions.
Patent Information
- Application Number
- PCT/KR2024/006254
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-04-02
- Filing Date
- 2024-05-09
- Publication Date
- 2024-11-14
AI Technical Summary
Current diagnostic methods for prostate cancer, such as PSA measurement and tissue biopsies, suffer from low accuracy and invasiveness, leading to overdiagnosis and overtreatment, necessitating a more precise and non-invasive approach for diagnosis and treatment prediction.
Utilization of miR-6880-5p in exosomes derived from cancer cells as a biomarker for diagnosing prostate cancer and predicting treatment response, allowing for non-invasive blood-based testing and pharmaceutical interventions to inhibit cancer progression.
Enhances diagnostic accuracy and reduces the need for invasive biopsies, providing a biomarker for predicting treatment response and inhibiting prostate cancer metastasis, even in hormone-resistant cases, through increased miR-6880-5p levels in cancer cells, thereby reducing proliferation, migration, and invasion abilities.
Smart Images

Figure KR2024006254_14112024_PF_FP_ABST
Abstract
Description
MIR-6880-5P as a diagnostic and therapeutic target for prostate cancer
[0001] The present invention relates to miR-6880-5p as a diagnostic and therapeutic target for prostate cancer, and specifically provides a use of miR-6880-5p in exosomes derived from cancer cells for prostate cancer diagnosis and a use of miR-6880-5p for prostate cancer treatment.
[0002] Prostate cancer (PCa) is the second most common malignant tumor among men worldwide. According to the 2019 National Cancer Registry, the cancer incidence rate increased by 3.6% year-on-year, with prostate cancer ranking sixth (16,803 cases) among cancer types. While the incidence of stomach cancer, colon cancer, and liver cancer, which are more common than prostate cancer, has been declining over the past decade, the incidence of prostate cancer has been steadily increasing since 1999.
[0003] Prostate cancer exhibits diverse intratumor heterogeneity. Tumor heterogeneity refers to the differences in genotype and phenotypic information of cells within a tumor, observed differently depending on the location. Depending on the degree, this heterogeneity can influence drug response and treatment resistance. Therefore, understanding tumor formation and progression patterns through the degree of tumor heterogeneity is crucial for selecting a patient's treatment approach. Currently, prostate cancer diagnosis and prognosis are predicted through methods such as PSA (Prostate Specific Antigen) measurement, ultrasound, CT, MRI, and histopathological examination using tissue samples.
[0004] PSA is an enzyme secreted by prostate cells into semen, with a small amount secreted into the blood. Therefore, PSA testing is performed based on blood PSA levels, and most healthy individuals have levels below 4 ng / ml. Abnormally elevated levels are considered to indicate conditions such as benign prostatic hyperplasia, prostatitis, and prostate cancer. However, the accuracy of diagnosing prostate cancer in the PSA gray zone is only about 30%, which can lead to overdiagnosis and overtreatment. Therefore, a biopsy is required for an accurate diagnosis, and the appropriate treatment method is selected through a pathological tissue biopsy, taking into account factors such as the clinical stage, malignancy of the cancer cells, and other diseases. However, biopsy is not only difficult to perform depending on the location, size, and condition of the tumor, but it is also invasive, which carries risks for both patients and physicians. Therefore, a simpler and more accurate diagnostic technique is needed.
[0005] The present invention provides a method for diagnosing and predicting the prognosis of prostate cancer, including miR-6880-5p in exosomes. This blood-based diagnostic method reduces the risk of tissue biopsy and overcomes the low accuracy rate of conventional PSA gray zone tests, enabling more accurate and rapid prostate cancer diagnosis.
[0006] In addition, it is an object of the present invention to provide a biomarker capable of predicting the prognosis of a therapeutic response to endocrine therapy.
[0007] In addition, the present invention aims to provide a kit for predicting prostate cancer metastasis or prognosis comprising the composition.
[0008] In addition, the present invention was completed by confirming the reduced expression pattern of miR-6880-5p in prostate cancer and confirming that the proliferation, migration, and invasion ability of cancer can be reduced by positively regulating the expression of miR-6880-5p.
[0009] Accordingly, the present invention provides miR-6880-5p as a target for preventing and treating prostate cancer and inhibiting its metastasis, and provides a pharmaceutical composition for preventing or treating prostate cancer comprising the miRNA itself or a vector expressing the same as an active ingredient, and a pharmaceutical composition for preventing prostate cancer metastasis.
[0010] However, the technical problems to be solved by the present invention are not limited to the problems mentioned above, and other problems not mentioned can be clearly understood by those skilled in the art from the description below.
[0011] The present invention provides miR-6880-5p in exosomes isolated from plasma as a biomarker for diagnosing prostate cancer and predicting the prognosis of treatment response.
[0012] In addition, the present invention provides a biomarker composition for diagnosing prostate cancer and predicting the prognosis of treatment response, which comprises miR-6880-5p in exosomes separated from plasma as an active ingredient.
[0013] As one embodiment of the present invention, the exosome may be a cancer-derived exosome, and the cancer-derived exosome may be isolated using a CD63-specific antibody.
[0014] In addition, the present invention provides a composition for diagnosing prostate cancer and predicting the prognosis of treatment response, comprising as an active ingredient a preparation capable of measuring the expression level of miR-6880-5p in exosomes separated from plasma.
[0015] As one embodiment of the present invention, the agent capable of measuring the expression level of the miR-6880-5p may be an oligonucleotide comprising a nucleotide sequence complementary to part or all of the miR-6880-5p, and a non-limiting example thereof may be a primer or probe specific to the miR-6880-5p.
[0016] In addition, the present invention provides a method for diagnosing prostate cancer and a method for providing information for diagnosing prostate cancer, comprising the steps of: isolating exosomes from a liquid biopsy isolated from a subject requiring diagnosis of prostate cancer; measuring the expression level of miR-6880-5p in the exosomes; and determining that the subject has prostate cancer if the expression level of miR-6880-5p is lower than that of a normal subject.
[0017] In addition, the present invention provides a method for determining the suitability of a treatment method in a prostate cancer patient by performing the following steps before and after the cancer treatment step: isolating exosomes from a liquid biopsy isolated from the patient; measuring the expression level of miR-6880-5p in the exosomes; and determining that the treatment prognosis is likely to be good if the expression level of miR-6880-5p after the treatment is significantly higher than the expression level of miR-6880-5p before the treatment, and determining that the treatment prognosis is likely to be poor if the expression level of miR-6880-5p is significantly lower than the expression level of miR-6880-5p before the treatment.
[0018] In addition, the present invention provides a pharmaceutical composition for preventing or treating prostate cancer, comprising miR-6880-5p or a vector expressing the same as an active ingredient.
[0019] In addition, the present invention provides a pharmaceutical composition for preventing prostate cancer metastasis, comprising miR-6880-5p or a vector expressing the same as an active ingredient.
[0020] The present invention provides miR-6880-5p as a biomarker that can diagnose prostate cancer more simply and quickly using a non-invasive method, and provides the miRNA as a target for the prevention and treatment of prostate cancer and inhibition of its metastasis, so that by increasing the level of miR-6880-5p in cancer cells, the survival, proliferation, migration, and invasion capabilities of prostate cancer can be reduced, and further, it exhibits an anticancer effect even in malignant prostate cancer that exhibits resistance to hormone therapy, and thus it is expected to be used in various ways for the treatment of prostate cancer.
[0021] Figure 1 shows the results of analyzing the characteristics of cancer cell-derived exosomes isolated from the blood of prostate cancer patients.
[0022] Figure 2 shows differentially expressed genes in exosomes derived from the blood of prostate cancer patients and normal individuals.
[0023] Figure 3 is a graph comparing the expression levels of miR-6880-5p in blood-derived exosomes from prostate cancer patients and normal individuals.
[0024] Figure 4 is a graph showing the change in the expression level of miR-6880-5p before and after endocrine therapy in the PR group with a good treatment response and the PD group with a poor treatment response.
[0025] Figure 5 compares the expression levels of miR-6880-5p in various types of prostate cancer cells.
[0026] Figure 6a confirms that proliferation is reduced when miR-6880-5p is transfected in PC3 cells.
[0027] Figure 6b confirms that proliferation is reduced when miR-6880-5p is transfected in DU145 cells.
[0028] Figure 6c shows the results of a wound healing assay confirming the migratory ability of PC3 cells following miR-6880-5p transfection.
[0029] Figure 6d shows the results of a wound healing assay confirming the migratory ability of DU145 cells following miR-6880-5p transfection.
[0030] Figure 6e shows the results of a cell invasion analysis confirming the invasiveness of PC3 cells following miR-6880-5p transfection.
[0031] Figure 6f shows the results of a cell invasion analysis confirming the invasiveness of DU145 cells following miR-6880-5p transfection.
[0032] Figure 7a shows the results of differential expression gene analysis between the untreated control group and DU145 cells transfected with miR-6880-5p mimic.
[0033] Figure 7b shows the results of differential expression gene analysis between DU145 cells transfected with a negative control or miR-6880-5p mimic.
[0034] Figure 7c is a mosaic map showing the expression patterns of genes related to angiogenesis and cell migration by expression of miR-6880-5p.
[0035] Figures 7d, 7f and 7g show signaling pathways downregulated by expression of miR-6880-5p.
[0036] Figures 7e, 7h, and 7i show signaling pathways upregulated by expression of miR-6880-5p.
[0037] Figure 8 shows the results of an MTT assay confirming a decrease in cell viability following miR-6880-5p transfection.
[0038] The present inventors have conducted a thorough study on a method for diagnosing prostate cancer using a non-invasive method, identified low levels of miR-6880-5p in exosomes isolated from the blood of prostate cancer patients, and provided miR-6880-5p as a biomarker for diagnosing prostate cancer.
[0039] Meanwhile, the inventors of the present invention confirmed the change in the expression level of miR-6880-5p before and after endocrine therapy treatment in groups with a good prognosis and groups with a poor prognosis. As a result, it was confirmed that in the group with a good prognosis, a low level of miR-6880-5p increased after treatment, and in the group with a poor prognosis, a relatively high level of miR-6880-5p was shown and its expression level decreased after treatment.
[0040] Accordingly, the present inventors provide miR-6880-5p as a biomarker for predicting treatment response in prostate cancer patients.
[0041] The present invention is characterized by using microRNA biomarkers as noninvasive tools for diagnosing prostate cancer and predicting therapeutic response to endocrine therapy in prostate cancer patients.
[0042] More specifically, the present invention provides a technology for determining that a patient in a sample has prostate cancer by measuring the expression level of miRNA-6880-5p present in the sample and, if miRNA-6880-5p is relatively underexpressed,
[0043] In the present invention, the transcript base sequence of miRNA-6880-5p is 5'-UGGUGGAGGAAGAGGGCAGCUC-3' (SEQ ID NO: 1) (Accession Number: MIMAT0027660).
[0044] In the present invention, the case where miRNA-6880-5p is relatively underexpressed is based on the expression level of miRNA-6880-5p in exosomes isolated from the plasma of a normal person. In order to determine that the patient of the sample in question has prostate cancer, the expression level must be about 0.8 times or less than the expression level of miRNA-6880-5p of a normal person, and preferably, an underexpression of about 0.6 times or less must be confirmed.
[0045] Various agents capable of detecting microRNA can be used to measure the expression level of miRNA-6880-5p present in a sample.
[0046] In the present invention, “diagnosis” includes determining the susceptibility of an individual to a specific disease or condition, determining whether an individual currently has a specific disease or condition, determining the prognosis of an individual suffering from a specific disease or condition, or therametrics (e.g., monitoring the condition of an individual to provide information about the efficacy of a treatment).
[0047] In addition, the prostate cancer diagnostic kit of the present invention may include a preparation capable of measuring the expression level of miRNA-6880-5p from a biological sample, wherein the preparation means a molecule that can be used to detect the biomarker of the present invention by confirming the expression level of miRNA-6880-5p.
[0048] In the present invention, an antisense oligonucleotide, primer, probe, and / or antibody that specifically binds to miRNA-6880-5p can be used as a miRNA-6880-5p expression level measuring agent, and the expression level of miRNA-6880-5p can be measured by a known method used to measure the level of gene expression, for example, performing PCR using a primer or performing a hybridization reaction using a probe. In addition, the kit may include various tools and reagents known in the art that facilitate detection, for example, a suitable carrier, a labeling substance capable of generating a detectable signal, a stabilizer, etc., in addition to the measuring agent.
[0049] In the present invention, the biological sample used to measure the expression level of miRNA-6880-5p may be a non-invasive sample, and the non-invasive sample may be a liquid biopsy, i.e., blood, serum, plasma, urine, or saliva, preferably blood, serum, or plasma, and more preferably plasma, but is not limited thereto.
[0050] In the present invention, miRNA-6880-5p is a concept that includes functional equivalents of the oligonucleotides constituting it, for example, variants and mimics that can perform the same function functionally as the microRNA-6880-5p nucleic acid molecule, although some of the base sequences of the miRNA-6880-5p oligonucleotide have been modified by deletion, substitution, or insertion.
[0051] In the present invention, a "primer" refers to a short nucleic acid sequence with a short free hydroxyl group that can form base pairs with a complementary template and serves as a starting point for template strand replication. The primer of the present invention can be chemically synthesized using methods known in the art, such as, for example, the phosphoramidite solid support method.
[0052] In the present invention, the term "probe" refers to a nucleic acid fragment, such as RNA or DNA, consisting of several to several hundred bases capable of specifically binding to miRNA and labeled to enable detection of the presence or absence of a specific miRNA. The probe may be produced in the form of an oligonucleotide probe, a single-stranded DNA probe, a double-stranded DNA probe, an RNA probe, etc., and may be labeled with biotin, FITC, rhodamine, DIG, etc., or with a radioisotope, etc.
[0053] In the present invention, the kit may be a kit including, but is not limited to, the essential elements required for performing RT-PCR. For example, in the case of an RT-PCR kit, in addition to each primer pair specific for a marker gene, the kit may include a test tube or other appropriate container, a reaction buffer, deoxynucleotides (dNTPs), Taq polymerase and reverse transcriptase, DNase, RNase inhibitor, DEPC water, sterile water, and the like.
[0054] In addition, the present invention can provide a method for diagnosing prostate cancer and a method for providing information for diagnosing prostate cancer, including the steps of isolating exosomes from a liquid biopsy isolated from an individual in need of diagnosis of prostate cancer; measuring the expression level of miR-6880-5p in the exosomes; and determining that the exosomes are prostate cancer if the expression level of miR-6880-5p is lower than that of a normal individual.
[0055] The measurement of the above miRNA expression level can be performed by, but is not limited to, RT-PCR, competitive RT-PCR, real-time RT-PCR, quantitative RT-PCR, RNase protection assay (RPA), Northern blotting, or DNA chip method.
[0056] In the present invention, prevention means all acts of delaying the occurrence of prostate cancer by administering the composition according to the present invention, treatment means suppressing the survival and proliferation of prostate cancer by administering the pharmaceutical composition according to the present invention, and “metastasis” in the present invention means that prostate cancer moves away from the site of occurrence, and prevention or suppression of metastasis means all acts of reducing the movement and invasiveness of prostate cancer cells to reduce the departure of cancer cells from the site of occurrence.
[0057] In addition, the subject to whom the pharmaceutical composition of the present invention is administered is not limited to a mammal, but may preferably be a human, and more specifically, may be a prostate cancer patient.
[0058] The pharmaceutical composition of the present invention may further include suitable carriers, excipients, and diluents commonly used in the manufacture of pharmaceutical compositions.
[0059] In the present invention, the term "carrier" is also called a vehicle and refers to a compound that facilitates the addition of a protein or peptide into a cell or tissue. For example, dimethyl sulfoxide (DMSO) is a commonly used carrier that facilitates the introduction of many organic substances into the cells or tissues of a living organism.
[0060] In the present invention, a "diluent" is defined as a compound that is diluted in water, which not only stabilizes the biologically active form of the target protein or peptide, but also dissolves the protein or peptide. Salts dissolved in buffer solutions are used as diluents in the art. A commonly used buffer solution is phosphate-buffered saline, as it mimics the salt state of human solutions. Since buffer salts can control the pH of a solution at low concentrations, it is rare for a buffer diluent to alter the biological activity of the compound. The compounds containing azelaic acid used herein can be administered to a human patient on their own, or as a pharmaceutical composition mixed with other ingredients, such as in combination therapy, or with suitable carriers or excipients.
[0061] In addition, the pharmaceutical composition for preventing or treating non-alcoholic steatohepatitis according to the present invention can be formulated and used in the form of external preparations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc. and sterile injection solutions according to conventional methods, and carriers, excipients, and diluents that can be included in the composition include lactose, dextrose, sucrose, oligosaccharides, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. When formulated, they are usually prepared using diluents or excipients such as fillers, bulking agents, binders, wetting agents, disintegrating agents, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, and capsules, and these solid preparations are prepared by mixing the above compound with at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, oral solutions, emulsions, and syrups, and in addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solutions and suspensions can include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.Suppository bases that can be used include witepsol, macrogol, tween 61, cocoa butter, laurin butter, and glycerogelatin.
[0062] The pharmaceutical composition of the present invention can be administered orally or parenterally, preferably parenterally, and in the case of parenteral administration, can be administered by intramuscular injection, intravenous injection, subcutaneous injection, intraperitoneal injection, local administration, transdermal administration, etc.
[0063] The appropriate dosage of the pharmaceutical composition of the present invention can be prescribed in various ways depending on factors such as the formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and reaction sensitivity.
[0064] The pharmaceutical composition of the present invention can be manufactured in the form of a unit dose or can be manufactured by inserting it into a large-capacity container by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method that can be easily performed by a person having ordinary skill in the art to which the present invention pertains. In this case, the formulation may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or in the form of an extract, powder, granules, tablet or capsule, and may additionally include a dispersing agent or stabilizer.
[0065] The present invention is susceptible to various modifications and embodiments. Specific embodiments are illustrated in the drawings and described in detail in the following detailed description. However, this is not intended to limit the present invention to specific embodiments, but rather to encompass all modifications, equivalents, and alternatives falling within the spirit and technical scope of the present invention. In describing the present invention, detailed descriptions of related known technologies will be omitted if they are deemed to obscure the gist of the present invention.
[0066]
[0067] [Example]
[0068] Example 1. Plasma separation
[0069] Blood from normal subjects and prostate cancer patients was centrifuged at 2,500 rpm for 7 minutes to separate plasma. The separated plasma was dispensed into cryovial tubes (550 μL each) and stored at -80°C until use in the experiment.
[0070]
[0071] Example 2. Exosome isolation
[0072] The separated plasma samples were pretreated in three steps.
[0073] 1) After centrifugation at 1,200g, 20 minutes, and 4℃, the supernatant was collected.
[0074] 2) The supernatant was centrifuged once more at 10,000g, 30 minutes, and 4℃, and then the supernatant was collected.
[0075] 3) Finally, the separated supernatant was filtered using a 0.2 ㎛ syringe to remove large molecules.
[0076] Samples that had undergone pretreatment were incubated with immunomagnetic beads conjugated with CD63 antibody, an exosome surface marker, for 2 hours using a roller, and exosomes were isolated using elution buffer. The isolated exosomes were stored at -80°C until used in the experiments.
[0077]
[0078] Example 3. Exosome identification
[0079] The size and concentration of the isolated exosomes were analyzed using a NanoSight LM10. After diluting 1:10 in PBS, the exosomes were injected into the sample measurement chamber using a 1 mL syringe, minimizing bubble formation. Data analysis was performed using NTA Version 2.3 Build 0034 software.
[0080] Through this experiment, the size, concentration, and shape of the isolated exosomes were checked to confirm whether they were exosomes (Fig. 1).
[0081]
[0082] Example 4. Selection of miRNAs in exosomes for prostate cancer diagnosis.
[0083] After thawing plasma stored at -80℃, exosomes were isolated using CD63 antibody-conjugated immunomagnetic beads. miRNAs from exosomes were isolated using Invitrogen (Cat No. 4478545) according to the manufacturer's instructions. Total RNA extracted from exosomes was labeled with a fluorescent dye using the FlsachTag Biotin RNA Labeling Kit to synthesize cDNA. Double-stranded DNA was converted to single-stranded DNA for hybridization. The resulting cDNA was then hybridized to GeneChip miRNA 4.0 microarrays. All arrays were measured by an Affymetrix Gene Chip Scanner 3000, and the data were analyzed using Transcriptome Analysis Console™ (TAC) software. Differentially expressed genes were identified in the normalized miRNA data set using the R programming language (Fig. 2).
[0084]
[0085] This study identified miRNAs differentially expressed in plasma-derived exosomes between normal individuals and prostate cancer patients. In these results, PR stands for Partial Response, indicating a patient with a good response to treatment. PD stands for Progressive Disease, indicating the development of one or more new lesions despite treatment. However, the blood samples from prostate cancer patients used in this study were obtained before endocrine therapy. The results showed that miR-6880-5p showed significantly lower expression levels in the PD group and relatively higher expression levels in the normal and PR groups. Therefore, it can be concluded that the expression of miR-6880-5p in exosomes can distinguish between prostate cancer patients and normal individuals and is associated with the response to endocrine therapy in prostate cancer patients (Figure 4).
[0086]
[0087] Example 5. Confirmation of miRNA expression levels in exosomes: qRT-PCR (Quantitative real-time polymerase chain reaction)
[0088] Total RNA in exosomes was isolated, and cDNA was synthesized using the TaqMan MicroRNA Reverse Transcription Kit and a primer with the sequence of has-miR-6880-5p (assay ID 467246_mat; 5'-UGGUGGAGGAAGAGGGCAGCUC-3'). 7 μl of the reverse transcription kit mixture (100 mM dNTPs, MultiScribe Reverse Transcriptase, 10X Reverse Transcription Buffer, RNase inhibitor, Nuclease-free water), 3 μl of 5X RT primer, and 5 μl of RNA were added per sample (Table 1). PCR was performed under the following conditions: 16°C for 30 min, 42°C for 30 min, 85°C for 5 min, and 4°C infinity. The kit and primers for cDNA synthesis were purchased from Applied Biosystems, and PCR was performed according to the manufacturer's instructions. 1.33 μl of synthesized cDNA, TaqMan master mix (2x), has-miR-6880-5p probe (TaqMan assay (20x)), and Ultra Pure water were mixed to a total volume of 20 μl and dispensed into a 96-well standard (0.2 ml) plate (Table 2). qRT-PCR was performed at 50°C for 2 min for 1 cycle, 95°C for 10 min for 1 cycle, and 40 cycles of 95°C for 15 s and 60°C for 60 s to measure the expression of miR-6880-5p.
[0089]
[0090] In this study, we confirmed the expression level of miR-68805p in blood-derived exosomes of prostate cancer patients compared to healthy subjects. By confirming that the expression of miR-6880-5p was decreased in prostate cancer patients compared to healthy subjects, we can confirm that the expression of miR-6880-5p in exosomes is related to prostate cancer (Fig. 3). In addition, we confirmed the expression of miR-6880-5p before and after endocrine therapy in the PR and PD groups of prostate cancer. In the PR group, the expression of miR-6880-5p increased after treatment (FU, follow-up) compared to before treatment (BL, baseline), whereas in the PD group, the expression of miR-6880-5p decreased after treatment compared to before treatment (Fig. 4).
[0091]
[0092] ComponentVolume (1 reaction)100mM dNTPs (with dTTP)0.15 μLMutiScribe TM Reverse Transcriptase, 50 U / μL1.00 μL10
[0093]
[0094] ComponentVolume per reaction384-well or 96-well fast [0.1 mL] plate96-well standard [0.2mL] plateTaqMan TM Small RNA Assay [20X]0.50 μL1.00 μLPCR Master Mix5.00 μL10.00 μLNuclease-free water3.84 μL7.67 μLTotal PCR Reaction Mix volume9.34 μL18.67 μL
[0095]
[0096] Example 6. Cell culture
[0097] In this study, the normal prostate epithelial cell line RWPE-1, the hormone-responsive prostate cancer cell line LNCaP, and the castration-resistant prostate cancer cell lines DU145 and PC3 were used. RWPE-1 was cultured in Keratinocyte serum-free medium containing 0.05 mg / mL BPD, 0.005 μg / mL epidermal growth factor, and 1% penicillin-streptomycin, while LNCaP, DU145, and PC3 cell lines were cultured in RPMA-1640 medium containing 10% FBS and 1% penicillin-streptomycin. All cells were cultured in an incubator at 37°C and 5% CO2.
[0098]
[0099] Example 7. Confirmation of miRNA expression levels in prostate cancer cells.
[0100] To determine the expression of miR-6880-5p in different prostate cancer types, miRNA was isolated from normal prostate epithelial cells and prostate cancer cells using QIAzol reagent, miRNeasy Mini kit (Qiagen, Cat No. 217004) according to the manufacturer's instructions. cDNA was synthesized using the same method used to determine the expression of miRNA obtained from exosomes, and expression of miR-6880-5p in prostate cancer cells was confirmed using qRT-PCR.
[0101] As a result, we found that miR-6880-5p expression was lowest in RWPE-1, LNCaP, DU145, and PC3, in that order (Fig. 5). These results suggest that miR-6880-5p expression levels can be used to predict prognosis for each type of prostate cancer.
[0102]
[0103] Example 8. Confirmation of cell proliferation, migration, and invasion abilities according to miR-6880-5p regulation in prostate cancer cells.
[0104] To determine whether the level of miR-6880-5p expression affects the characteristics of prostate cancer cells, prostate cancer cell lines DU145 and PC3 cells were transfected with miR-6880-5p mimic and inhibitor using Lipofectamin RNAimax (Cat No. 13778075). Specifically, transfection of miR-6880-5p mimic and inhibitor was performed using Cationinc lipid-based reagent of Lipofectamin RNAimax (Cat No. 13778075) according to the manufacturer's guidelines. The miRNA to be transfected and Lipofectamin RNAimax were diluted using Opti-MEM Medium. The miRNA mimic was diluted to 1, 5, or 10 nM, and the miRNA inhibitor was diluted to 50 nM. NC was also performed using the same method. Next, the diluted miRNA and NC were mixed with Lipofectamin RNAimax in a 1:1 ratio to form miRNA-lipid complexes. The formed complexes were injected into cells at 60-80% confluence in a 6-well plate and cultured in a 37°C incubator for 24 hours.
[0105] Product information for miR-6880-5p inhibitor / mimic is as shown in Table 3 below.
[0106] miRBase IDAssay IDProduct TypeCatalog No.hsa-miR-6880-5pAM27166Ambion® Anti-miR™ miRNA InhibitorAM17000PM27166Ambion® Pre-miR™ miRNA PrecursorAM17100
[0107]
[0108] - Cell viability assay
[0109] Transfected cells were seeded into 96-well plates. After culturing in an incubator for 24, 48, and 72 hours, they were stained with 3-(4,5 dimethylthiazol-2-yl)-2,5-disphenyltetrazolium bromide. Cell viability was measured at a wavelength of 595 nm using a microplate reader.
[0110]
[0111] - Cell wound healing assay
[0112] Transfected cells were seeded into 24-well plates and stabilized in an incubator for 24 hours. Immediately after creating a wound by scraping the cell layer with a sterile 200 μL plastic pipette tip (0 h), images were taken using an optical microscope. After an additional 24 hours of culture, images were taken using an optical microscope to determine changes in cell migration compared to each negative control group.
[0113]
[0114] - Cell invasion assay (Trans-well assay)
[0115] To analyze the invasion capacity of cells, a 24-well transwell chamber (Costar) was used. Serum-free medium and 200 μL of transfected cells were dispensed into the upper chamber (8.0 μm pore size), and 750 μL of complete medium was dispensed into the lower chamber. After culturing in an incubator for 48 h, the upper and lower chambers were washed with PBS. Cells on the lower membrane surface of the upper chamber were fixed with 4% paraformaldehyde and methanol and stained with 0.1% crystal violet. Cells on the upper membrane surface were removed with a cotton swab. Invasion images were captured using an optical microscope, and the number of invaded cells was measured in four random areas.
[0116]
[0117] Both PC3 and DU145 cells mimicking miR-6880-5p showed significantly suppressed cell proliferation, migration, and invasion compared to the negative control group, whereas cells with suppressed miR-6880-5p showed significantly increased proliferation compared to the negative control group. These results confirmed that miR-6880-5p expression directly regulates the proliferation (Figures 6a and 6b), migration (Figures 6c and 6d), and invasion (Figures 6e and 6f) abilities of cancer cells.
[0118]
[0119] Example 9. Analysis of gene functions regulated by miR-6880-5p expression.
[0120] Total RNA was isolated from DU145 cells transfected with miR-6880-5p mimic (6880_mi), negative control (NC), and untreated (Con) DU145 cells using Trizol reagent according to the manufacturer's instructions. Total RNA concentration was measured using Nanodrop (Thermo Scientific). RNA quality was assessed using an Agilent 2100 bioanalyzer with an RNA 6000 nano chip (Agilent Technologies). The library for RNA sequencing analysis was prepared using the QunatSeq Library Prep kit (Lexogen), and high-throughput sequencing was performed using NextSeq 500 (Illumina). The entire transcriptome was used to identify differentially expressed genes (DEGs) that were more than twice as expressed in the cell group transfected with miR-6880-5p mimic. DEGs were analyzed using ExDEA software (Ebiogen), and gene classification was based on DAVID, Kyoto Encyclopedia of Gens and Genomes (KEGG) pathway, and STRING. Heatmaps were analyzed using MultiExperiment Viewer software (MeV, V4.9.0).
[0121]
[0122] All significantly differentially expressed genes (DEGs) were classified into 14 GO categories using the ExDEA software. Genes involved in angiogenesis and cell migration by miR-6880-5p expression were downregulated at the highest rate compared to the control and negative controls (Figs. 7a to 7c). Furthermore, the signaling pathways of DEGs according to miR-6880-5p overexpression were analyzed using the KEGG pathway. Compared to the control and negative controls, genes downregulated by miR-6880-5p overexpression were associated with eight major signaling pathways (Ras signaling pathway, MAPK signaling pathway, cancer pathway, cellular senescence, ErbB signaling pathway, EGFR tyrosine kinase inhibitor resistance, and AMPK signaling pathway) (Figs. 7d, 7f, and 7g). Angiogenesis is known to promote cancer metastasis by regulating cell invasion, proliferation, and migration (Melegh Z et al., 2019, Int J Mol. 31;20(11):2676). In addition, Ras and MAPK have been reported to play important roles in the development of metastatic prostate cancer, and ErbB promotes tumor growth by reactivating androgen receptor expression in patients with castration-resistant prostate cancer (Kojima M et al., 2012, Cancer Res. 72: 1878-89; Gao S et al., 2016, Clin Cancer. 22: 3672-82). And the genes upregulated by overexpression of miR-6880-5p were related to nine major signaling pathways (cell cycle, autophagy, FoxO signaling pathway, cancer pathway, Hippo signaling pathway, ferroptosis, mitophagy, HIF-1 signaling pathway, and cellular senescence) (Figures 7e, 7h, and 7i). FoxO signaling pathway, ferroptosis, and mitophagy are closely related to apoptosis and antitumor immunity (reviewed in Ashrafizadeh M et al., 2022, J Exp Clin Cancer Res. 41: 105]; Wang Y et al., 2022, Prostate Cancer and Prostate Diseases. doi:10.1038 / s41391-022-00583-w]). In particular, FoxO is known as a tumor suppressor gene involved in cell differentiation, apoptosis, cell cycle arrest, DNA damage, and repair (Shan Z et al., 2019, J Cell Mol Med. 23: 3130-9).
[0123] Therefore, we found that genes downregulated by miR-6880-5p overexpression were closely related to tumor promotion, whereas upregulated genes were associated with regulating cell proliferation and apoptosis. These results suggest that miR-6880-5p may function as a tumor suppressor miRNA.
[0124]
[0125] Example 10. Confirmation of antitumor effects through miR-6880-5p expression regulation.
[0126] We confirmed the apoptotic effect of miR-6880-5p expression regulation in prostate cancer. The experiment was performed according to the time sequence shown in Table 4 below.
[0127] Day 0Day 1Day 2Day 3Day 4Day 5Seeding(2.5*10 5 cells / well)Transfection (24h)Re-seeding(2.5*10 5 cells / well)Enz 10uM, 20uM treat (48h)MTT treat (0.5mg / ml, 1h
[0128]
[0129] Enzalutamide, a drug used to treat prostate cancer, was used as a positive control to confirm the therapeutic effect of miR-6880-5p mimic.
[0130] MTT assay results confirmed a significant decrease in the viability of prostate cancer cells transfected with miR-6880-5p (Fig. 8). Compared to enzalutamide alone, the miR-6880-5p mimic significantly reduced cancer cell viability, confirming that the antitumor effect of the miR-6880-5p mimic was independent of enzalutamide. Meanwhile, the antitumor effect of the miR-6880-5p mimic was more pronounced in the highly malignant PC3 cell line.
[0131]
[0132] Although the embodiments described above have been described with limited drawings, those skilled in the art will appreciate that various technical modifications and variations can be applied based on the above. For example, appropriate results can still be achieved even if the described techniques are performed in a different order than described, and / or components of the described systems, structures, devices, circuits, etc. are combined or combined in a different manner than described, or are replaced or substituted with other components or equivalents.
[0133] Therefore, other implementations, other embodiments, and equivalents to the claims also fall within the scope of the claims described below.
Claims
1. A pharmaceutical composition for preventing or treating prostate cancer, comprising miR-6880-5p or a vector expressing the same as an active ingredient.
2. In paragraph 1, A pharmaceutical composition wherein the above miR-6880-5p is an oligonucleotide consisting of the base sequence of sequence number 1.
3. In paragraph 1, A pharmaceutical composition, wherein the vector expressing the above miR-6880-5p comprises the base sequence of SEQ ID NO: 1 or a base sequence complementary thereto.
4. In paragraph 1, A pharmaceutical composition, wherein the above prostate cancer is a prostate cancer resistant to hormone therapy.
5. A pharmaceutical composition for preventing prostate cancer metastasis, comprising miR-6880-5p or a vector expressing the same as an active ingredient.
6. A biomarker composition for diagnosing prostate cancer, comprising miR-6880-5p in cancer cell-derived exosomes as an active ingredient.
7. In paragraph 6, The above cancer cell-derived exosomes were isolated from plasma, A biomarker composition wherein the above cancer cell-derived exosomes express CD63.
8. A composition for diagnosing prostate cancer, comprising as an active ingredient an agent capable of measuring the expression level of miR-6880-5p in exosomes derived from cancer cells.
9. In paragraph 8, A composition for diagnosing prostate cancer, wherein the agent capable of measuring the expression level of the above miR-6880-5p is an oligonucleotide containing a nucleotide sequence complementary to part or all of the above miR-6880-5p. 10.(1) A step of isolating cancer cell-derived exosomes from a liquid biopsy isolated from an individual requiring diagnosis of prostate cancer; (2) a step of measuring the expression level of miR-6880-5p in the exosome; and (3) A method for diagnosing prostate cancer and a method for providing information for diagnosing prostate cancer, including a step of determining that the patient has prostate cancer if the expression level of the miR-6880-5p is lower than that of a normal person.
11. In paragraph 10, An information providing method, wherein the above step (1) is performed using an immuno-magnetic bead combined with a CD63 antibody.
12. In paragraph 10, A method of providing information, wherein the liquid biopsy is blood, plasma, or serum.
13. How to determine the suitability of treatment in prostate cancer patients by performing the following steps before and after cancer treatment: (a) isolating cancer cell-derived exosomes from a liquid biopsy isolated from the patient; (b) a step of measuring the expression level of miR-6880-5p in the exosome; and (c) A step of determining that the prognosis of treatment is good if the expression level of miR-6880-5p after treatment is significantly higher than that before treatment, and determining that the prognosis of treatment is poor if the expression level is significantly lower than that before treatment.
Citation Information
Patent Citations
Prostate cancer detection kit or device, and detection method
KR102401689B1
Body fluid extract containing micro RNA
WO2021049671A1
